Exploring how cannabinoid receptors affect the development of brain cells that produce myelin.
Official title: Investigating the role of cannabinoid receptors in oligodendrocyte development
Funded at Oregon Health & Science University · NIH-11006321 · Data updated 2026-11-12
This study is looking at how certain receptors in the brain might help the cells that make myelin, which is important for protecting nerves, and it hopes to find new ways to treat conditions like multiple sclerosis that affect myelin.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | February 1, 2023 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $46,622 |
| NIH project number | 5F31NS130898-03 |
| Project ID | NIH-11006321 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with neurological conditions that involve myelin disruption, particularly those with multiple sclerosis.
✕Less likely to help
Patients with conditions unrelated to myelin production or neurological function may not receive any benefit from this research.
What this research studies
This research investigates the role of cannabinoid receptors in the development of oligodendrocytes, the cells responsible for producing myelin in the central nervous system. By understanding the molecular mechanisms that drive oligodendrocyte development and myelination, the study aims to uncover potential therapeutic targets for neurological diseases like multiple sclerosis. The research utilizes proteomic analysis of cultured rat oligodendrocytes to identify key proteins involved in myelination, particularly focusing on the endocannabinoid system's influence during the differentiation of oligodendrocyte precursor cells. Patients may benefit from insights gained that could lead to new treatment options for myelin-related disorders.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating neurological diseases characterized by myelin damage, such as multiple sclerosis.
How similar studies have gone: Previous research has shown promise in targeting the endocannabinoid system for neurological conditions, suggesting potential for success in this area.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Miramontes, Tania G — Oregon Health & Science University
- Study coordinator: Miramontes, Tania G
Related research
Other NIH-funded projects on the same topics.
-
Understanding how a protein affects nerve cell movement in Alzheimer's disease
This study is looking at how a protein called APP affects the growth and movement of nerve cells, which is important for understanding Alzheimer's disease, and it aims to find out how problems with this protein might lead to nerve cell damage.
-
Understanding how the bone marrow environment drives AML resistance
A large NIH-funded project at Oregon Health & Science University is studying how the body’s own cell surroundings help acute myeloid leukemia become resistant to treatment, with potential paths to better therapies for patients.
-
Improving Safety at Work with a Low-Resource mHealth Program in Malaysia (and beyond)
A low-cost mobile health program to improve safety culture in Malaysian workplaces, with plans to adapt the approach for U.S. workers in high-risk industries.
-
Oregon Healthy Workplace Initiative for Better Health
A multi-site effort aims to improve the health and safety of workers by coordinating research, tools, and interventions across workplaces.
-
Understanding how AML cells become resistant to therapy over time
This project looks at why acute myeloid leukemia stops responding to treatment and how to design better drug combinations to prevent relapse.
-
Mechanisms and Countermeasures for Ultra-Potent Synthetic Opioid Overdose
A small, focused NIH grant aims to understand why ultra-potent synthetic opioids cause severe overdose and to explore potential countermeasures to keep people safe.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.